SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

Nirogacestat Also In Anti-BCMA Combo, Ovarian Cancer Studies

 
• By Mandy Jackson

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

FDA approved written on translucent black space
SpringWorks will file for approval in Europe next year • Source: Shutterstock

More from New Products

More from Scrip